Leo CEO Bourdon Plots Return To Profit This Year
As Early-Stage R&D Is Axed
The Danish group has cut 300 jobs to shift to an external innovation sourcing model that will make Leo more competitive in the dermatology space and help it break even this year, CEO Christophe Bourdon tells Scrip.
You may also be interested in...
With mirikizumab delayed until Lilly overcomes the FDA’s manufacturing concerns, the company has fallen behind on its goal of five approvals in 2023.
Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.
The company reported positive topline results from a second trial of its topical pan-JAK inhibitor, delgocitinib, in chronic hand eczema.